NASDAQ : DFTX
Definium Therapeutics, Inc. — Financial statements
United States
Last price 37.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.10B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 72.90M | 48.64M | 38.62M | 41.74M | 30.16M | 58.77M |
| Research & Development | 154.65M | 117.67M | 65.30M | 52.12M | 36.17M | 34.79M |
| Operating Expenses | 227.54M | 166.31M | 103.92M | 93.87M | 66.33M | 93.55M |
| Operating Income | -227.54M | -166.31M | -103.92M | -93.87M | -66.33M | -93.55M |
| Interest Expense | -5.02M | -5.48M | -2.28M | -920.00K | -359.00K | |
| Interest & Investment Income | 12.80M | 10.96M | 11.56M | 5.58M | 1.50M | |
| Currency Exchange Gain (Loss) | -139.00K | -131.00K | -638.00K | 157.00K | 195.00K | -86.00K |
| Other Non Operating Income (Expenses) | -133.88M | -22.83M | -15.94M | -6.69M | 7.84M | 106.00K |
| EBT Excluding Unusual Items | -353.79M | -183.79M | -111.22M | -95.73M | -56.80M | -93.89M |
| Merger & Restructuring Charges | -300.00K | |||||
| Other Unusual Items | 2.54M | |||||
| Pretax Income | -353.79M | -183.79M | -108.68M | -95.73M | -56.80M | -94.19M |
| Income Tax Expense | -1.16M | |||||
| Net Income | -353.79M | -183.79M | -108.68M | -95.73M | -56.80M | -93.04M |
| Net Income to Common | -353.79M | -183.79M | -108.68M | -95.73M | -56.80M | -93.04M |
| Shares Outstanding (Basic) | 101.59M | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M |
| Shares Outstanding (Diluted) | 101.59M | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M |
| EPS (Basic) | -3.48 | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 |
| EPS (Diluted) | -3.48 | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 |
| EBITDA | -166.28M | -103.89M | -66.31M | -93.54M | ||
| D&A For EBITDA | 27.00K | 27.00K | 16.00K | 16.00K | ||
| EBIT | -227.54M | -166.31M | -103.92M | -93.87M | -66.33M | -93.55M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 655.27M | 257.84M | 273.74M | 99.70M | 142.14M | 133.54M |
| Short-Term Investments | 428.61M | 153.76M | ||||
| Cash & Short-Term Investments | 1.08B | 411.59M | 273.74M | 99.70M | 142.14M | 133.54M |
| Prepaid Expenses | 8.22M | 7.73M | 7.88M | 4.17M | 3.91M | 3.68M |
| Total Current Assets | 1.09B | 419.32M | 281.62M | 103.87M | 146.06M | 137.22M |
| Goodwill | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M |
| Other Intangible Assets | 527.00K | 3.69M | 6.87M | |||
| Other Long-Term Assets | 880.00K | 862.00K | 613.00K | 224.00K | 331.00K | |
| Total Assets | 1.11B | 440.10M | 302.15M | 124.54M | 169.99M | 164.00M |
| Accounts Payable | 6.96M | 5.35M | 2.01M | 4.14M | 2.11M | 4.18M |
| Accrued Expenses | 37.22M | 20.45M | 12.83M | 11.63M | 5.88M | 6.23M |
| Other Current Liabilities | 113.02M | 40.91M | 24.01M | 16.48M | 9.90M | |
| Total Current Liabilities | 157.20M | 66.70M | 38.85M | 32.25M | 17.89M | 10.41M |
| Long-Term Debt | 36.47M | 40.58M | 21.85M | 14.13M | ||
| Other Long-Term Liabilities | 549.00K | 496.00K | 32.00K | 1.18M | 1.93M | |
| Total Liabilities | 194.22M | 107.77M | 60.70M | 46.41M | 19.08M | 12.34M |
| Additional Paid-In Capital | 1.74B | 913.91M | 639.51M | 367.99M | 344.76M | 288.29M |
| Retained Earnings | -818.76M | -582.67M | -398.88M | -290.20M | -194.47M | -137.67M |
| Comprehensive Income & Other | 417.00K | 1.08M | 819.00K | 343.00K | 627.00K | 1.05M |
| Shareholders' Equity | 918.68M | 332.33M | 241.45M | 78.13M | 150.92M | 151.66M |
| Total Liabilities & Equity | 1.11B | 440.10M | 302.15M | 124.54M | 169.99M | 164.00M |
| Total Debt | 36.47M | 40.58M | 21.85M | 14.13M | ||
| Net Cash (Debt) | 1.05B | 371.01M | 251.89M | 85.58M | 142.14M | 133.54M |
| Net Cash Per Share | 10.31 | 4.15 | 3.57 | 2.19 | 4.61 | 4.88 |
| Filing Date Shares Outstanding | 134.37M | 99.70M | 75.37M | 41.33M | 38.06M | 28.58M |
| Total Common Shares Outstanding | 134.37M | 98.78M | 75.10M | 41.10M | 37.98M | 28.55M |
| Working Capital | 934.90M | 352.62M | 242.77M | 71.63M | 128.16M | 126.81M |
| Book Value Per Share | 6.84 | 3.36 | 3.21 | 1.90 | 3.97 | 5.31 |
| Tangible Book Value | 898.76M | 312.41M | 221.53M | 57.69M | 127.31M | 124.88M |
| Tangible Book Value Per Share | 6.69 | 3.16 | 2.95 | 1.40 | 3.35 | 4.37 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -353.79M | -183.79M | -108.68M | -95.73M | -56.80M | -93.04M |
| Depreciation & Amortization | -38.00K | -20.00K | 16.00K | |||
| Other Amortization | 527.00K | 3.30M | 4.70M | 2.60M | ||
| Loss (Gain) From Sale of Investments | -172.00K | -1.82M | ||||
| Stock-Based Compensation | 35.74M | 21.56M | 17.67M | 15.49M | 13.71M | 42.72M |
| Other Operating Activities | 134.73M | 23.06M | 14.69M | 6.33M | -7.95M | |
| Change in Accounts Payable | 2.75M | 3.34M | -2.13M | 2.02M | -2.06M | 1.28M |
| Change in Other Net Operating Assets | 12.79M | 6.10M | -1.22M | 4.26M | -1.73M | 1.75M |
| Operating Cash Flow | -167.95M | -131.56M | -79.13M | -64.36M | -50.14M | -45.82M |
| Cash Acquisitions | -297.00K | |||||
| Investment in Securities | -224.35M | -151.61M | ||||
| Investing Cash Flow | -224.35M | -151.61M | -297.00K | |||
| Long-Term Debt Issued | 42.00M | 10.00M | 15.00M | |||
| Long-Term Debt Repaid | -22.00M | |||||
| Net Debt Issued (Repaid) | 20.00M | 10.00M | 15.00M | |||
| Issuance of Common Stock | 1.08B | 263.66M | 259.97M | 7.69M | 43.21M | 98.82M |
| Repurchase of Common Stock | -54.00K | -407.00K | ||||
| Other Financing Activities | -62.36M | -16.39M | -16.72M | -844.00K | 16.25M | |
| Financing Cash Flow | 1.01B | 267.27M | 253.20M | 21.85M | 59.05M | 98.82M |
| Foreign Exchange Rate Adjustments | -18.00K | -7.00K | -30.00K | 79.00K | -309.00K | 742.00K |
| Net Cash Flow | 621.88M | -15.90M | 174.04M | -42.44M | 8.60M | 53.45M |
| Levered Free Cash Flow | 7.61M | -57.81M | -45.28M | -26.39M | -15.82M | -8.21M |
| Unlevered Free Cash Flow | 10.75M | -54.39M | -43.85M | -25.91M | -15.82M | -7.99M |
| Cash Interest Paid | 4.27M | 5.34M | 2.22M | 534.00K | ||
| Change in Working Capital | 15.54M | 9.44M | -3.34M | 6.28M | -3.78M | 1.88M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 4.36B | 1.32B | 510.39M | 146.75M | 82.66M | 590.17M |
| Enterprise Value | 3.32B | 1.15B | 239.42M | 43.12M | -71.79M | 444.25M |
| Last Close Price | 32.47 | 13.39 | 6.96 | 3.66 | 2.20 | 20.70 |
| PB Ratio | 4.75 | 3.97 | 2.11 | 1.88 | 0.55 | 3.89 |
| P/TBV Ratio | 4.85 | 4.22 | 2.30 | 2.54 | 0.65 | 4.73 |
| Debt / Equity Ratio | 0.04 | 0.12 | 0.09 | 0.18 | ||
| Net Debt / Equity Ratio | -1.14 | -1.12 | -1.04 | -1.09 | -0.94 | -0.88 |
| Net Debt / EBITDA Ratio | 2.23 | 2.42 | 2.14 | 1.43 | ||
| Quick Ratio | 6.89 | 6.17 | 7.05 | 3.09 | 7.94 | 12.83 |
| Current Ratio | 6.95 | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 |
| Return on Equity (ROE) | -64.09% | -64.06% | -68.01% | -83.59% | -37.54% | -81.78% |
| Return on Assets (ROA) | -20.64% | -28.01% | -30.44% | -39.84% | -24.82% | -47.63% |
| Return on Capital Employed (ROCE) | -23.80% | -44.50% | -39.50% | -101.70% | -43.60% | -60.90% |
| Earnings Yield | -10.72% | -13.93% | -21.29% | -65.24% | -68.71% | -15.76% |
| Buyback Yield / Dilution | -22.22% | -26.78% | -79.94% | -26.90% | -12.71% | -54.25% |